دورية أكاديمية
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC.
| العنوان: | Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. |
|---|---|
| المؤلفون: | Zhou N; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA., Velez MA; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA., Bachrach B; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA., Gukasyan J; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA., Fares CM; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA., Cummings AL; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA., Lind-Lebuffe JP; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA., Akingbemi WO; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA., Li DY; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA., Brodrick PM; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA., Yessuf NM; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA., Rettinger S; Department of Endocrinology, Providence Health & Services, Santa Monica, CA, USA., Grogan T; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA., Rochigneux P; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France., Goldman JW; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA., Garon EB; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA., Lisberg A; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: alisberg@mednet.ucla.edu. |
| المصدر: | Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2021 Nov; Vol. 161, pp. 34-41. Date of Electronic Publication: 2021 Aug 30. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Limerick : Elsevier Scientific Publishers Original Publication: Amsterdam, The Netherlands : Elsevier, c1985- |
| مواضيع طبية MeSH: | Carcinoma, Non-Small-Cell Lung*/drug therapy , Lung Neoplasms*/drug therapy, Humans ; Immune Checkpoint Inhibitors ; Retrospective Studies ; Thyroid Gland |
| مستخلص: | Introduction: Thyroid dysfunction is the most frequent endocrine immune related adverse event (irAE) in non-small cell lung cancer (NSCLC), typically arising 3-6 months into immune checkpoint inhibitor (ICI) therapy, but arising after ICI cessation, in some cases. Due to limited post-treatment adverse event reporting requirements on ICI trials, the incidence of ICI-induced thyroid dysfunction arising after therapy is unclear. We investigated ICI-induced thyroid dysfunction in a cohort of 294 NSCLC patients, with a specific focus on the post-treatment setting. Methods: Retrospective analysis of ICI-induced thyroid dysfunction (clinically acted upon or laboratory only) was performed in 294 UCLA NSCLC patients treated 2012-2018. Clinically acted upon thyroid dysfunction was defined as thyroid diagnosis documentation and/or thyroid medication administration. Laboratory only dysfunction was defined as abnormal thyroid labs in the absence of clinical action. Timing of thyroid dysfunction relative to ICI treatment and thyroid monitoring patterns were also assessed. Results: 82% (241/294) of ICI treated NSCLC patients had thyroid labs during treatment. Of these 241 patients, 13% (31/241) had clinically acted upon thyroid dysfunction prior to, 8% (18/241) during, and 4% (9/241) after ICI. Most patients, 66% (159/241), did not have thyroid labs after ICI, but in the 53 patients with labs and no prior clinical dysfunction, 17% (9/53) developed clinical dysfunction after ICI. In these 9 patients, median time from ICI initiation to dysfunction was 253 days. Two patients with post-treatment laboratory only dysfunction were observed. Conclusions: ICI-induced thyroid dysfunction arising post-treatment appears more common than previously appreciated, warranting additional evaluation. (Copyright © 2021 Elsevier B.V. All rights reserved.) |
| References: | Eur Thyroid J. 2018 Aug;7(4):167-186. (PMID: 30283735) Endocr Relat Cancer. 2014 Mar 07;21(2):371-81. (PMID: 24610577) Lancet. 2016 Apr 9;387(10027):1540-1550. (PMID: 26712084) Clin Cancer Res. 2014 May 1;20(9):2424-32. (PMID: 24583799) Cancer Res. 2017 Mar 15;77(6):1322-1330. (PMID: 28031229) J Immunother Cancer. 2019 Jul 3;7(1):165. (PMID: 31269983) PLoS One. 2016 Jun 03;11(6):e0156925. (PMID: 27257805) Horm Metab Res. 2019 Mar;51(3):145-156. (PMID: 30861560) Thyroid. 2014 Dec;24(12):1670-751. (PMID: 25266247) N Engl J Med. 2015 Oct 22;373(17):1627-39. (PMID: 26412456) Thyroid Res. 2019 Feb 8;12:2. (PMID: 30774717) N Engl J Med. 2019 Nov 21;381(21):2020-2031. (PMID: 31562796) Thyroid. 2016 Oct;26(10):1343-1421. (PMID: 27521067) N Engl J Med. 2017 Jun 22;376(25):2415-2426. (PMID: 28636851) Nat Rev Dis Primers. 2020 May 7;6(1):38. (PMID: 32382051) Nat Rev Clin Oncol. 2016 Aug;13(8):473-86. (PMID: 27141885) J Clin Oncol. 2018 Jun 10;36(17):1714-1768. (PMID: 29442540) J Endocrinol Invest. 2018 May;41(5):549-556. (PMID: 29043574) Eur J Cancer. 2020 May;130:39-50. (PMID: 32172197) Immunotargets Ther. 2017 Aug 24;6:51-71. (PMID: 28894725) N Engl J Med. 2015 May 21;372(21):2018-28. (PMID: 25891174) Ann Intern Med. 2015 May 5;162(9):641-50. (PMID: 25798805) Ann Oncol. 2017 Mar 1;28(3):583-589. (PMID: 27998967) J Adv Pract Oncol. 2015 Mar-Apr;6(2):99-106. (PMID: 26649243) Ther Adv Endocrinol Metab. 2019 Dec 25;10:2042018819896182. (PMID: 31903179) Front Pharmacol. 2017 Oct 18;8:730. (PMID: 29093678) Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii40-vii48. (PMID: 31816084) Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii59-vii67. (PMID: 31816080) N Engl J Med. 2015 Jul 9;373(2):123-35. (PMID: 26028407) Cancer Immunol Res. 2018 Mar;6(3):288-294. (PMID: 29382669) Oncologist. 2018 Oct;23(10):1236-1241. (PMID: 29769383) Cancers (Basel). 2021 Apr 17;13(8):. (PMID: 33920721) J Clin Oncol. 2010 Jul 1;28(19):3167-75. (PMID: 20516446) Oncologist. 2014 Jan;19(1):34-43. (PMID: 24309982) |
| معلومات مُعتمدة: | K08 CA245249 United States CA NCI NIH HHS; P30 CA016042 United States CA NCI NIH HHS; R01 CA208403 United States CA NCI NIH HHS; UL1 TR001881 United States TR NCATS NIH HHS |
| فهرسة مساهمة: | Keywords: Anti-PD-(L)1 therapy; Immune checkpoint inhibitor (ICI); Immune related adverse events (irAE); Non-small cell lung cancer (NSCLC); Thyroid dysfunction |
| المشرفين على المادة: | 0 (Immune Checkpoint Inhibitors) |
| تواريخ الأحداث: | Date Created: 20210910 Date Completed: 20211022 Latest Revision: 20220317 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8923054 |
| DOI: | 10.1016/j.lungcan.2021.08.009 |
| PMID: | 34507111 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1872-8332 |
|---|---|
| DOI: | 10.1016/j.lungcan.2021.08.009 |